Duyckaerts C, Delatour B, Potier MC: Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118: 5–36. 10.1007/s00401-009-0532-1
Article
CAS
PubMed
Google Scholar
Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12: 383–388.
Article
CAS
PubMed
Google Scholar
Selkoe DJ: The molecular pathology of Alzheimer’s disease. Neuron 1991, 6: 487–498. 10.1016/0896-6273(91)90052-2
Article
CAS
PubMed
Google Scholar
Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Mueller-Hill B: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325: 733–736. 10.1038/325733a0
Article
CAS
PubMed
Google Scholar
Glenner GG, Wong CW: Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120: 885–890. 10.1016/S0006-291X(84)80190-4
Article
CAS
PubMed
Google Scholar
Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K: Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. The EMBO journal 1985, 4: 2757–2763.
PubMed Central
CAS
PubMed
Google Scholar
Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256: 184–185. 10.1126/science.1566067
Article
CAS
PubMed
Google Scholar
Price JL, Morris JC: Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999, 45: 358–368. 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
Article
CAS
PubMed
Google Scholar
Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999, 274: 6483–6492. 10.1074/jbc.274.10.6483
Article
CAS
PubMed
Google Scholar
Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HW, Pradier L, Bayer TA: Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 2004, 164: 1495–1502. 10.1016/S0002-9440(10)63235-X
Article
PubMed Central
PubMed
Google Scholar
Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8: 101–112. 10.1038/nrm2101
Article
CAS
PubMed
Google Scholar
Wirths O, Multhaup G, Bayer TA: A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade. J Neurochem 2004, 91: 513–520. 10.1111/j.1471-4159.2004.02737.x
Article
CAS
PubMed
Google Scholar
Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, Schymkowitz J, Rousseau F: Lipids revert inert A[beta] amyloid fibrils to neurotoxic protofibrils that affect learning in mice. The EMBO journal 2008, 27: 224–233. 10.1038/sj.emboj.7601953
Article
PubMed Central
CAS
PubMed
Google Scholar
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci 1985, 82: 4245–4249. 10.1073/pnas.82.12.4245
Article
PubMed Central
CAS
PubMed
Google Scholar
Näslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P: Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci 1994, 91: 8378–8382. 10.1073/pnas.91.18.8378
Article
PubMed Central
PubMed
Google Scholar
Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S: Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3(pE), in senile plaques. Neuron 1995, 14: 457–466. 10.1016/0896-6273(95)90301-1
Article
CAS
PubMed
Google Scholar
Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K: Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993, 301: 41–52. 10.1006/abbi.1993.1112
Article
CAS
PubMed
Google Scholar
Prelli F, Castano E, Glenner GG, Frangione B: Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 1988, 51: 648–651. 10.1111/j.1471-4159.1988.tb01087.x
Article
CAS
PubMed
Google Scholar
He W, Barrow CJ: The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 1999, 38: 10871–10877. 10.1021/bi990563r
Article
CAS
PubMed
Google Scholar
Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y: Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific Abeta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13: 45–53. 10.1016/0896-6273(94)90458-8
Article
CAS
PubMed
Google Scholar
Pike CJ, Overman MJ, Cotman CW: Amino-terminal Deletions Enhance Aggregation of beta-Amyloid Peptides in Vitro. J Biol Chem 1995, 270: 23895–23898. 10.1074/jbc.270.41.23895
Article
CAS
PubMed
Google Scholar
Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG, Shearman MS, Kalaria RN: Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-β(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006, 32: 103–118. 10.1111/j.1365-2990.2006.00696.x
Article
CAS
PubMed
Google Scholar
Mori H, Takio K, Ogawara M, Selkoe DJ: Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 1992, 267: 17082–17086.
CAS
PubMed
Google Scholar
Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S: Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 1996, 215: 173–176. 10.1016/0304-3940(96)12970-0
Article
CAS
PubMed
Google Scholar
Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K: Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 2010, 120: 185–193. 10.1007/s00401-010-0690-1
Article
PubMed Central
CAS
PubMed
Google Scholar
Walsh DM, Selkoe DJ: A beta oligomers - a decade of discovery. J Neurochem 2007, 101: 1172–1184. 10.1111/j.1471-4159.2006.04426.x
Article
CAS
PubMed
Google Scholar
Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK: Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 2004, 24: 3592–3599. 10.1523/JNEUROSCI.5167-03.2004
Article
CAS
PubMed
Google Scholar
Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ: The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39: 10831–10839. 10.1021/bi001048s
Article
CAS
PubMed
Google Scholar
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999, 155: 853–862. 10.1016/S0002-9440(10)65184-X
Article
PubMed Central
CAS
PubMed
Google Scholar
McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46: 860–866. 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
Article
CAS
PubMed
Google Scholar
Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE: Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996, 271: 4077–4081. 10.1074/jbc.271.8.4077
Article
CAS
PubMed
Google Scholar
Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P: Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994, 200: 1598–1603. 10.1006/bbrc.1994.1634
Article
CAS
PubMed
Google Scholar
Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H: A Mouse Model of Amyloid beta Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo. J Neurosci 2010, 30: 4845–4856. 10.1523/JNEUROSCI.5825-09.2010
Article
CAS
PubMed
Google Scholar
Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA: N-truncated amyloid beta (Abeta) 4–42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol 2013, 126: 189–205. 10.1007/s00401-013-1129-2
Article
PubMed Central
CAS
PubMed
Google Scholar
Hahn S, Brüning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S: Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. J Neurochem 2011, 116: 385–395. 10.1111/j.1471-4159.2010.07118.x
Article
CAS
PubMed
Google Scholar
Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA: Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 2010, 117: 85–96. 10.1007/s00702-009-0314-x
Article
PubMed Central
CAS
PubMed
Google Scholar
Pillot T, Drouet B, Queillé S, Labeur C, Vandekerckhove J, Rosseneu M, Pinçon-Raymond M, Chambaz J: The Nonfibrillar Amyloid β-Peptide Induces Apoptotic Neuronal Cell Death. J Neurochem 1999, 73: 1626–1634.
Article
CAS
PubMed
Google Scholar
Youssef I, Florent-Béchard S, Malaplate-Armand C, Koziel V, Bihain B, Olivier J-L, Leininger-Muller B, Kriem B, Oster T, Pillot T: N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging 2008, 29: 1319–1333. 10.1016/j.neurobiolaging.2007.03.005
Article
CAS
PubMed
Google Scholar
Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R: Intraneuronal beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation. J Neurosci 2006, 26: 10129–10140. 10.1523/JNEUROSCI.1202-06.2006
Article
CAS
PubMed
Google Scholar
Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O: Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 2012,33(196):e129–196. e140
Google Scholar
Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA: Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol 2008, 116: 647–655. 10.1007/s00401-008-0451-6
Article
CAS
PubMed
Google Scholar
Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, Farrer M, Hutton M, Lincoln S, Hardy J, Gwinn K, Somer M, Paetau A, Kalimo H, Ylikoski R, Poyhonen M, Kucera S, Haltia M: A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1 [see comments]. Nat Med 1998, 4: 452–455. 10.1038/nm0498-452
Article
CAS
PubMed
Google Scholar
Basun HBNIM, et al.: CLinical and neuropathological features of the arctic app gene mutation causing early-onset alzheimer disease. Arch Neurol 2008, 65: 499–505. 10.1001/archneur.65.4.499
Article
PubMed Central
PubMed
Google Scholar
Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L: The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced A[beta] protofibril formation. Nat Neurosci 2001, 4: 887–893. 10.1038/nn0901-887
Article
CAS
PubMed
Google Scholar
Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1: 345–347. 10.1038/ng0892-345
Article
CAS
PubMed
Google Scholar
Snowdon DA: Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist 1997, 37: 150–156. 10.1093/geront/37.2.150
Article
CAS
PubMed
Google Scholar
Bayer TA, Wirths O: Intracellular accumulation of amyloid-beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci 2010, 2: 1–10.
Google Scholar
Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006, 368: 387–403. 10.1016/S0140-6736(06)69113-7
Article
CAS
PubMed
Google Scholar
Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee J-M: Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci 2009, 106: 20324–20329. 10.1073/pnas.0911281106
Article
PubMed Central
CAS
PubMed
Google Scholar
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440: 352–357. 10.1038/nature04533
Article
CAS
PubMed
Google Scholar
Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL: Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002, 924: 133–140. 10.1016/S0006-8993(01)03058-X
Article
CAS
PubMed
Google Scholar
Kim J, Basak JM, Holtzman DM: The Role of Apolipoprotein E in Alzheimer's Disease. Neuron 2009, 63: 287–303. 10.1016/j.neuron.2009.06.026
Article
PubMed Central
CAS
PubMed
Google Scholar
Jawhar S, Wirths O, Bayer TA: Pyroglutamate Abeta - a hatchet man in Alzheimer disease. J Biol Chem 2011, 286: 38825–38832. 10.1074/jbc.R111.288308
Article
PubMed Central
CAS
PubMed
Google Scholar
Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Rönicke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rübsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth H-U, von Hörsten S: Selective Hippocampal Neurodegeneration in Transgenic Mice Expressing Small Amounts of Truncated Aβ Is Induced by Pyroglutamate–Aβ Formation. J Neurosci 2011, 31: 12790–12801. 10.1523/JNEUROSCI.1794-11.2011
Article
CAS
PubMed
Google Scholar
Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L: Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated A{beta}42 Accumulation in a Novel Alzheimer Transgenic Model. Am J Pathol 2004, 165: 1289–1300. 10.1016/S0002-9440(10)63388-3
Article
PubMed Central
CAS
PubMed
Google Scholar
Christensen DZ, Bayer TA, Wirths O: Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging 2010, 31: 1153–1163. 10.1016/j.neurobiolaging.2008.07.022
Article
CAS
PubMed
Google Scholar
Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA: Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 2009, 118: 487–496. 10.1007/s00401-009-0557-5
Article
PubMed Central
PubMed
Google Scholar
Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA: Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 2002, 9: 88–102.
CAS
PubMed
Google Scholar
Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA: Identification of low molecular weight pyroglutamate Abeta oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem 2010, 285: 41517–41524. 10.1074/jbc.M110.178707
Article
PubMed Central
CAS
PubMed
Google Scholar
Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE: Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 2001, 276: 12991–12998. 10.1074/jbc.M007859200
Article
CAS
PubMed
Google Scholar
Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ: Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008, 28: 4231–4237. 10.1523/JNEUROSCI.5161-07.2008
Article
PubMed Central
CAS
PubMed
Google Scholar
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416: 535–539. 10.1038/416535a
Article
CAS
PubMed
Google Scholar
Benilova I, Karran E, De Strooper B: The toxic A[beta] oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012, 29: 349–357.
Article
Google Scholar
Bitan G, Fradinger EA, Spring SM, Teplow DB: Neurotoxic protein oligomers–what you see is not always what you get. Amyloid 2005, 12: 88–95. 10.1080/13506120500106958
Article
PubMed
Google Scholar
Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG: Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 2006, 45: 15157–15167. 10.1021/bi061850f
Article
CAS
PubMed
Google Scholar
Barrow CJ, Zagorski MG: Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 1991, 253: 179–182. 10.1126/science.1853202
Article
CAS
PubMed
Google Scholar
Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, Nishimura M, Iwata N, Van Broeckhoven C, Ihara Y, Saido TC: Potent amyloidogenicity and pathogenicity of A[beta]43. Nat Neurosci 2011, 14: 1023–1032. 10.1038/nn.2858
Article
CAS
PubMed
Google Scholar
Welander H, Frånberg J, Graff C, Sundström E, Winblad B, Tjernberg LO: Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 2009, 110: 697–706. 10.1111/j.1471-4159.2009.06170.x
Article
CAS
PubMed
Google Scholar
Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ: beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci 1993, 90: 10836–10840. 10.1073/pnas.90.22.10836
Article
PubMed Central
CAS
PubMed
Google Scholar
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth H-U, Blennow K, Wirths O, Bayer TA: Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease. J Biol Chem 2012, 287: 8154–8162. 10.1074/jbc.M111.308601
Article
PubMed Central
CAS
PubMed
Google Scholar
Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David JP, Vanmechelen E, Sergheraert C, Delacourte A: Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003, 85: 1581–1591. 10.1046/j.1471-4159.2003.01818.x
Article
CAS
PubMed
Google Scholar
Haupt C, Leppert J, Ronicke R, Meinhardt J, Yadav JK, Ramachandran R, Ohlenschlager O, Reymann KG, Gorlach M, Fandrich M: Structural basis of beta-amyloid-dependent synaptic dysfunctions. Angew Chem Int Ed Engl 2012, 51: 1576–1579. 10.1002/anie.201105638
Article
CAS
PubMed
Google Scholar
Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO: Structural conversion of neurotoxic amyloid-[beta]1–42 oligomers to fibrils. Nat Struct Mol Biol 2010, 17: 561–567. 10.1038/nsmb.1799
Article
PubMed Central
CAS
PubMed
Google Scholar
Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y: Evidence of fibril-like beta-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's beta-amyloid. Nat Struct Mol Biol 2007, 14: 1157–1164. 10.1038/nsmb1345
Article
CAS
PubMed
Google Scholar
Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R: A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002, 99: 16742–16747. 10.1073/pnas.262663499
Article
PubMed Central
CAS
PubMed
Google Scholar
Scheidt HA, Morgado I, Rothemund S, Huster D, Fandrich M: Solid-state NMR spectroscopic investigation of Abeta protofibrils: implication of a beta-sheet remodeling upon maturation into terminal amyloid fibrils. Angew Chem Int Ed Engl 2011, 50: 2837–2840. 10.1002/anie.201007265
Article
CAS
PubMed
Google Scholar
Scheidt HA, Morgado I, Rothemund S, Huster D: Dynamics of amyloid beta fibrils revealed by solid-state NMR. J Biol Chem 2012, 287: 2017–2021. 10.1074/jbc.M111.308619
Article
PubMed Central
CAS
PubMed
Google Scholar
Sevalle J, Amoyel A, Robert P, Fournie-Zaluski MC, Roques B, Checler F: Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem 2009, 109: 248–256. 10.1111/j.1471-4159.2009.05950.x
Article
CAS
PubMed
Google Scholar
Cynis H, Schilling S, Bodnar M, Hoffmann T, Heiser U, Saido TC, Demuth HU: Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim Biophys Acta 2006, 1764: 1618–1625. 10.1016/j.bbapap.2006.08.003
Article
CAS
PubMed
Google Scholar
Jawhar S, Wirths O, Schilling S, Graubner S, Demuth HU, Bayer TA: Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem 2011, 286: 4454–4460. 10.1074/jbc.M110.185819
Article
PubMed Central
CAS
PubMed
Google Scholar
Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU: Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett 2004, 563: 191–196. 10.1016/S0014-5793(04)00300-X
Article
CAS
PubMed
Google Scholar
Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S: Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med 2008, 14: 1106–1111. 10.1038/nm.1872
Article
CAS
PubMed
Google Scholar